Revisión narrativa de la terapia inhalatoria en la EPOC

Referencias bibliográficas

• 2023 Gold Report - Global Initiative for Chronic Obstructive Lung Disease. GOLD [consultado 2 Mar 2023]. Disponible en: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf
• M. Miravitlles, M. Calle, J. Molina, P. Almagro, J.T. Gómez, J.A. Trigueros, et al. [Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD] Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol., 58 (2022), pp. 69-81, 10.1016/j.arbres.2021.03.005
• J.J. Soler-Cataluña, P. Piñera, J.A. Trigueros, M. Calle, C. Casanova, B.G. Cosío, et al. [Spanish COPD Guidelines (GesEPOC). 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome] Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC. Arch Bronconeumol., 58 (2022), pp. 159-170, 10.1016/j.arbres.2021.05.011
• B. Celli, L. Fabbri, G. Criner, F.J. Martinez, D. Mannino, C. Vogelmeier, et al. Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revisión. Am J Respir Crit Care Med., 206 (2022), pp. 1317-1325, 10.1164/rccm.202204-0671PP
• B.R. Celli, J.A. Wedzicha. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med., 381 (2019), pp. 1257-1266, 10.1056/NEJMra1900500
• M. MacLeod, A. Papi, M. Contoli, B. Beghé, B.R. Celli, J.A. Wedzicha, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology., 26 (2021), pp. 532-551, 10.1111/resp.14041
• J.J. Soler-Cataluña, P. Piñera, J.A. Trigueros, M. Calle, C. Casanova, B.G. Cosío, et al. Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. Arch Bronconeumol., 58 (2022), pp. 159-170, 10.1016/j.arbres.2021.05.011
• Chronic Obstructive Pulmonary Disease in over 16s: Diagnosis and Management. National Institute for Health and Care Excellence (NICE); 2019 [consultado 2 Mar 2023]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK542426/
• Y. Suzuki, S. Sato, K. Sato, S. Inoue, Y. Shibata. Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Investig., 60 (2022), pp. 108-118, 10.1016/j.resinv.2021.08.002
• A. D’Urzo, G. Bader, S. Shen, P. Goyal, P. Altman. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: A post-hoc analysis of randomized trials. NPJ Prim Care Respir Med., 28 (2018), p. 18, 10.1038/s41533-018-0084-8
• M.I.A. Aziz, L.E. Tan, D.B. Wu, F. Pearce, G.S.W. Chua, L. Lin, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: A systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 3203-3231, 10.2147/COPD.S173472
• A. Koarai, H. Sugiura, M. Yamada, T. Ichikawa, N. Fujino, T. Kawayama, et al. Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis. BMC Pulm Med., 20 (2020), p. 111, 10.1186/s12890-020-1152-8
• C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Mölken, K.M. Beeh, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med., 364 (2011), pp. 1093-1103, 10.1056/NEJMoa1008378
• M.L. Decramer, K.R. Chapman, R. Dahl, P. Frith, G. Devouassoux, C. Fritscher, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med., 1 (2013), pp. 524-533, 10.1016/S2213-2600(13)70158-9
• P. Rogliani, L. Calzetta, F. Braido, M. Cazzola, E. Clini, G. Pelaia, et al. LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review . Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 3115-3130, 10.2147/COPD.S170606
• A.S. Ismaila, K. Haeussler, A. Czira, V. Tongbram, M. Malmenäs, J. Agarwal, et al. Comparative efficacy of umeclidinium/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis. Adv Ther., 39 (2022), pp. 4961-5010, 10.1007/s12325-022-02234-x
• S.H. Lee, C.K. Rhee, K. Yoo, J.W. Park, S.J. Yong, J. Kim, et al. Direct switch from tiotropium to indacaterol/glycopyrronium in chronic obstructive pulmonary disease patients in Korea. Tuberc Respir Dis (Seoul)., 84 (2021), pp. 96-104, 10.4046/trd.2020.0109
• S. Muro, H. Yoshisue, K. Kostikas, P. Olsson, P. Gupta, J.A. Wedzicha. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. Respirology., 25 (2020), pp. 393-400, 10.1111/resp.13651
• A. Kaplan, K.R. Chapman, S.M. Anees, I. Mayers, D. Rochdi, M. Djandji, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: The POWER study. Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 249-260, 10.2147/COPD.S185485
• P. Kardos, I. Hagedorn-Peinz. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study — the FAVOR study. Int J Chron Obstruct Pulmon Dis., 13 (2017), pp. 69-77, 10.2147/COPD.S146189
• V. Benavides-Cordoba, S. Aviles, C. Ascuntar, L. Orozco, R. Mosquera, J. Rivera. Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients. Pulm Pharmacol Ther., 61 (2020), p. 101898, 10.1016/j.pupt.2020.101898
• J. Beaulieu, D. Jensen, D.E. O’Donnell, C. Brouillard, L. Tracey, S. Vincent, et al. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: The RED trial. Ther Adv Respir Dis., 14 (2020), 10.1177/1753466620939507
• Y. Gong, C. Lin, Y. Jin, R. Chen. The efficacy and cost-effectiveness of umeclidinium/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease. Can Respir J., 2022 (2022), p. 2878648, 10.1155/2022/2878648
• D. Slade, R. Ray, C. Moretz, G. Germain, F. Laliberté, Q. Shen, et al. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: A retrospective cohort study. BMC Pulm Med., 21 (2021), p. 253, 10.1186/s12890-021-01612-5
• R. Kalhan, D. Slade, R. Ray, C. Moretz, G. Germain, F. Laliberté, et al. Umeclidinium/vilanterol compared with fluticasone propionate/salmeterol, budesonide/formoterol, and tiotropium as initial maintenance therapy in patients with COPD who have high costs and comorbidities. Int J Chron Obstruct Pulmon Dis., 16 (2021), pp. 1149-1161, 10.2147/COPD.S298032
• D. Slade, R. Ray, C. Moretz, G. Germain, F. Laliberté, Q. Shen, et al. Hospital admission and readmission among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease. Pulm Ther., 7 (2021), pp. 203-219, 10.1007/s41030-021-00151-y
• M.C. Chan, E.C. Tan, M.C. Yang. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 1079-1088, 10.2147/COPD.S159103
• Y. Gong, Y. Lv, H. Liu, Q. Zheng, L. Li. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. Ther Adv Respir Dis., 16 (2022), 10.1177/17534666211066068
• H.W. Lee, J. Park, E.J. Jang, C.H. Lee. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respir Res., 21 (2020), p. 310, 10.1186/s12931-020-01540-8
• C.F. Weng, C.C. Wu, M.H. Wu, F.J. Lin. Comparison of clinical outcomes among different fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists in patients with COPD. Chest., 163 (2023), pp. 799-814, 10.1016/j.chest.2022.11.027
• S.L. Cheng. Comparison of effectiveness using different dual bronchodilator agents in chronic obstructive pulmonary disease treatment. J Clin Med., 10 (2021), p. 2649, 10.3390/jcm10122649
• M.J. Hsieh, N.H. Chen, S.L. Cheng, C.W. Tao, Y.F. Wei, Y.K. Wu, et al. Comparing clinical outcomes of tiotropium/olodaterol, umeclidinium/vilanterol, and indacaterol/glycopyrronium fixed-dose combination therapy in patients with chronic obstructive pulmonary disease in Taiwan: A multicenter cohort study. Int J Chron Obstruct Pulmon Dis., 17 (2022), pp. 967-976, 10.2147/COPD.S353799
• B. Sposato, E. Petrucci, A. Serafini, F. Lena, L.G. Lacerenza, A. Montagnani, et al. Which LABA/LAMA should be chosen in COPD patients in real life?. Pulm Pharmacol Ther., 71 (2021), p. 102076, 10.1016/j.pupt.2021.102076
• G. Requena, A. Czira, V. Banks, R. Wood, T. Tritton, C.M. Castillo, et al. Comparison of rescue medication prescriptions in patients with chronic obstructive pulmonary disease receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol in routine clinical practice in England. Int J Chron Obstruct Pulmon Dis., 18 (2023), pp. 1431-1444, 10.2147/COPD.S411437
• J. Li, S. dell’Aniello, P. Ernst, S. Suissa. Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of chronic obstructive pulmonary disease. Eur Respir J., 62 (2023), p. 2300538, 10.1183/13993003.00538-2023
• C. Moretz, L.G. Bengtson, L. Sharpsten, E. Koep, L. Le, J. Tong, et al. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 2047-2060, 10.2147/COPD.S2135
• M.T. Driessen, J. Whalen, B. Seewoodharry Buguth, L.A. Vallejo-Aparicio, I.P. Naya, Y. Asukai, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective [hay correcciones en Respir Res, 2019;20:18]. Respir Res., 19 (2018), p. 224, 10.1186/s12931-018-0916-7
• S.R. Palli, B. Xie, B. Chastek, C.A. Elliott, L.G.S. Bengtson. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. J Manag Care Spec Pharm., 27 (2021), pp. 810-824, 10.18553/jmcp.2021.20514
• S. Suissa, S. dell’Aniello, P. Ernst. Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. Respir Med., 189 (2021), p. 106645, 10.1016/j.rmed.2021.106645
• A.L. Aguilar-Shea, J. Bonis. COPD from an everyday primary care point of view. J Family Med Prim Care., 8 (2019), pp. 2644-2650, 10.4103/jfmpc.jfmpc_477_19
• P. Solidoro, F. Patrucco, D. Bagnasco. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting β-agonist combinations in patients with chronic obstructive pulmonary disease: A review. Expert Rev Respir Med., 13 (2019), pp. 1087-1094, 10.1080/17476348.2019.1665514
• E.G. Lee, Y. Kim, Y.I. Hwang, K.H. Yoo, S.E. Lee, K.Y. Jung, et al. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting β agonist in patients with COPD. Sci Rep., 13 (2023), p. 8183, 10.1038/s41598-023-35223-3
• S. Salvi, M.K. Jain, S. Krishnamurthy, A. Balki, R. Kodgule, M. Tandon, et al. Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD. Lung India., 39 (2022), pp. 517-524, 10.4103/lungindia.lungindia_136_22
• W.B. Feldman, J. Avorn, A.S. Kesselheim, J.J. Gagne. Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers. JAMA Intern Med., 183 (2023), pp. 685-695, 10.1001/jamainternmed.2023.1245
• N. Fukuda, N. Horita, A. Kaneko, A. Goto, T. Kaneko, E. Ota, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting β-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev., 6 (2023), p. CD012066, 10.1002/14651858.CD012066.pub3
• D.M.G. Halpin, K.J. Rothnie, V. Banks, A. Czira, C. Compton, R. Wood, et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis., 17 (2022), pp. 2417-2429, 10.2147/COPD.S370540
• M.T. Wang, J.H. Lai, Y.L. Huang, J.T. Liou, S.H. Cheng, C.W. Lin, et al. Comparative effectiveness and safety of different types of inhaled long-acting β2-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β2-agonist plus inhaled corticosteroid fixed-dose combinations in COPD. A propensity score-inverse probability of treatment weighting cohort study. Chest., 160 (2021), pp. 1255-1270, 10.1016/j.chest.2021.05.025
• Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, et al. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis. 2023;18:643-659. doi:10.2147/COPD.S405498
• M. Cazzola, P. Rogliani, R. Laitano, L. Calzetta, M.G. Matera. Beyond dual bronchodilation — Triple therapy, when and why. Int J Chron Obstruct Pulmon Dis., 17 (2022), pp. 165-180, 10.2147/COPD.S345263
• J. Bourbeau, M. Bafadhel, N.C. Barnes, C. Compton, V. Di Boscio, D.A. Lipson, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis., 16 (2021), pp. 499-517, 10.2147/COPD.S291967
• Gómez Sáenz JT. El papel de la triple terapia en el tratamiento actual de la EPOC. Respiratorio Atención Primaria. Abril de 2023, número 4. Disponible en: https://www.livemed.in/canales/respiratorio-en-la-red/respiratorio-atencion-primaria/numero-4/pdfs/relr-n4-el-papel-de-la-triple-terapia-en-el-tratamiento-actual-de-la-epoc.pdf
• P. Rogliani, J. Ora, F. Cavalli, M. Cazzola, L. Calzetta. Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: A meta-analysis and IBiS score. J Clin Med., 11 (2022), p. 4491, 10.3390/jcm11154491
• H.W. Lee, H.J. Kim, E.J. Jang, C.H. Lee. Comparisons of efficacy and safety between triple (inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β-agonist) therapies in chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. Respiration., 100 (2021), pp. 631-643, 10.1159/000515133
• K. Ohtsuka, N. Harada, A. Horiuchi, S. Umemoto, R. Kurabatashi, A. Yui, et al. Therapeutic response to single-inhaler triple therapies in moderate-to-severe COPD. Respir Care., 68 (2023), pp. 330-337, 10.4187/respcare.10188
• J. Vestbo, A. Papi, M. Corradi, V. Blazhko, I. Montagna, C. Francisco, et al., Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial. Lancet, 389 (2017), pp. 1919-1929, 10.1016/S0140-6736(17)30188-5
• S. Bansal, M. Anderson, A. Anzueto, N. Brown, C. Compton, T.C. Corbridge, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ Prim Care Respir Med., 31 (2021), p. 29, 10.1038/s41533-021-00241-z
• G.T. Ferguson, N. Brown, C. Compton, T.C. Corbridge, K. Dorais, C. Fogarty, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: Lung function and health status results from two replicate randomized controlled trials. Respir Res., 21 (2020), p. 131, 10.1186/s12931-020-01360-w
• A. Papi, J. Vestbo, L. Fabbri, M. Corradi, H. Prunier, G. Cohuet, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial. Lancet., 391 (2018), pp. 1076-1084, 10.1016/S0140-6736(18)30206-X
• K.F. Rabe, F.J. Martinez, G.T. Ferguson, C. Wang, D. Singh, J.A. Wedzicha, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med., 383 (2020), pp. 35-48, 10.1056/NEJMoa1916046
• D.A. Lipson, F. Barnhart, N. Brealey, J. Brooks, G.J. Criner, N.C. Day, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med., 378 (2018), pp. 1671-1680, 10.1056/NEJMoa1713901
• G.T. Ferguson, K.F. Rabe, F.J. Martinez, L.M. Fabbri, C. Wang, M. Ichinose, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med., 6 (2018), pp. 747-758, 10.1016/S2213-2600(18)30327-8
• S. Sethi, B. Clark, L.G.S. Bengtson, E.K. Buysman, S. Palli, A. Sargent, et al. Healthcare resource utilization, cost and clinical outcomes in patients diagnosed with COPD initiating tiotropium bromide/olodaterol versus fluticasone furoate/umeclidinium/vilanterol based on exacerbation history. Int J Chron Obstruct Pulmon Dis., 18 (2023), pp. 625-641, 10.2147/COPD.S386962
• S. Sethi, S.R. Palli, L.G.S. Bengtson, E.K. Buysman, B. Clark, A. Sargent, et al. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm., 29 (2023), pp. 791-806, 10.18553/jmcp.2023.22373
• S. Suissa, S. Dell’Aniello, P. Ernst. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in real-world clinical practice. Chest., 157 (2020), pp. 846-855, 10.1016/j.chest.2019.11.007
• E. De Nigris, C. Treharne, N. Brighton, U. Holmgren, A. Walker, J. Haughney. Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study. Int J Chron Obstruct Pulmon Dis., 17 (2022), pp. 2987-3000, 10.2147/COPD.S381138
• J.A. Trigueros, N. Garin, A. Baloira, S. Aceituno, A. Calvo, M. Prades, et al. Cost-effectiveness analysis of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain. Int J Chron Obstruct Pulmon Dis., 17 (2022), pp. 2905-2917, 10.2147/COPD.S384591
• R. Buhl, M. Dreher, M. Mattiucci-Guehlke, R. Emerson-Stadler, S. Eckhardt, C. Taube, et al. EVELUT®: A real-world, observational study assessing dyspnoea and symptom burden in COPD patients switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS. Adv Ther., 40 (2023), pp. 3263-3278, 10.1007/s12325-023-02524-y
• K.R. Chapman, J.R. Hurst, S.M. Frent, M. Larbig, R. Fogel, T. Guerin, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary Disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med., 198 (2018), pp. 329-339, 10.1164/rccm.201803-0405OC
• D. Singh, A. Papi, M. Corradi, I. Pavlišová, I. Montagna, C. Francisco, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet., 388 (2016), pp. 963-973, 10.1016/S0140-6736(16)31354-X
• D.A. Lipson, H. Barnacle, R. Birk, N. Brealey, N. Locantore, D.A. Lomas, et al. FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med., 196 (2017), pp. 438-446, 10.1164/rccm.201703-0449OC
• D.M.G. Halpin, R. Birk, N. Brealey, G.J. Criner, M.T. Dransfield, E. Hilton, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res., 4 (2018), pp. 00119-2017, 10.1183/23120541.00119-2017